By Matthew Roscoe •
Updated: 07 Sep 2022 • 16:01
Image of the Pfizer logo. Credit: Molly Woodward/Shutterstock.com
The US Food and Drug Administration (FDA) announced that Pfizer’s investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, has been granted Breakthrough Therapy Designation for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active vaccines of pregnant women.
“The FDA decision is informed by the interim analysis of a placebo-controlled Phase 2 study (NCT03765073), evaluating the safety and immunogenicity of GBS6 in healthy pregnant women aged 18 to 40 years, who were vaccinated during the second or early third trimester of pregnancy,” Pfizer said on Wednesday, September 7.
“The study remains ongoing, and Pfizer will publish outcomes from this clinical trial when it is completed.”
Annaliesa Anderson, PhD, Senior Vice President and Head of Vaccine Research & Development, Pfizer, said: “GBS infections can have a devastating effect on newborns and their families.
“While prenatal screening and antibiotics during childbirth help provide protection against GBS in developed countries, this approach is not fully protected in the first week of life; presents multiple challenges in low- and middle-income countries; and has not been shown effective in preventing disease globally in infants beyond the first week of life and through the vulnerable first three months of life.”
She added: “If approved for pregnant women, GBS6 could help protect newborns from the serious illnesses caused by this disease like meningitis, pneumonia, and sepsis – fulfilling a critical global public health need.
“We are encouraged by today’s decision and look forward to discussing GBS6 with the FDA and other regulatory agencies to potentially reduce neonatal deaths and positively impact the existing global disease burden of GBS.”
It should be noted that the FDA’s Breakthrough Therapy Designation is “designed to expedite the development and review of drugs and vaccines that are intended to treat or prevent serious conditions, and preliminary clinical evidence indicates that the drug or vaccine may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s).”
“This decision follows the FDA’s March 2017 decision to grant Fast Track status to GBS6. Fast Track status is a process designed to facilitate the development and expedite the review of new drugs and vaccines intended to treat or prevent serious conditions and address an unmet medical need.”
You can read the full statement from Pfizer here.
Thank you for taking the time to read this article. Do remember to come back and check The Euro Weekly News website for all your up-to-date local and international news stories and remember, you can also follow us on Facebook and Instagram.
Share this story
Subscribe to our Euro Weekly News alerts to get the latest stories into your inbox!
By signing up, you will create a Euro Weekly News account if you don't already have one. Review our
Originally from the UK, Matthew is based on the Costa Blanca and is a web reporter for The Euro Weekly News covering international and Spanish national news. Got a news story you want to share? Then get in touch at firstname.lastname@example.org.
Download our media pack in either English or Spanish.